SCHOTT Pharma revenue and financials
In the fiscal year ended September 2025, SCHOTT Pharma reported revenue of €986.21M (+3.04% year over year). Net income was €146.45M, a net margin of 14.9%.
Fiscal year ending in September. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +3.04%
- FY to Sep 2025 vs FY to Sep 2024
- Net income growth
- −2.16%
- FY to Sep 2025 vs FY to Sep 2024
- Net margin
- 14.9%
- FY to Sep 2024: 15.6%
How SCHOTT Pharma is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 11.0% a year on average over the last 5 years
Compound annual growth rate: from €584.23M in 2020 to €986.21M in 2025.
Revenue has grown for 5 fiscal years in a row
Each fiscal year compared with the one before, up to 2025.
Operating margin fell from 20.5% to 18.8%
Operating income over revenue, 2022 → 2025: 1.6 percentage points.
Less cash than profit: free cash flow equal to 27% of net income
Totals for fiscal years 2023–2025: free cash flow €121.48M, net income €447.98M.
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | FY to Sep 2025 | FY to Sep 2024 | FY to Sep 2023 | FY to Sep 2022 | FY to Sep 2021 | FY to Sep 2020 |
|---|---|---|---|---|---|---|
| Total revenue | 986 | 957 | 899 | 821 | 649 | 584 |
| Cost of revenue | 654 | 634 | 582 | 525 | 422 | 388 |
| Gross profit | 332 | 323 | 316 | 297 | 226 | 196 |
| Selling, general and administrative | 131 | 125 | 123 | 111 | 92.5 | 89.6 |
| Research and development | 27.9 | 24.3 | 26.8 | 23.5 | 22.3 | 23.6 |
| Operating income | 186 | 189 | 171 | 168 | 115 | 91.0 |
| EBIT | 186 | 189 | 171 | 168 | 115 | 91.0 |
| EBITDA | 260 | 249 | 218 | 212 | 151 | 125 |
| Interest expense | 19.3 | 12.8 | 6.7 | 2.1 | 1.2 | 1.5 |
| Pre-tax income | 188 | 184 | 186 | 158 | 123 | 95.3 |
| Income tax | 40.8 | 33.6 | 33.9 | 32.4 | 22.1 | 17.7 |
| Net income | 146 | 150 | 152 | 125 | 101 | 77.5 |
| Net income to common shareholders | 146 | 150 | 152 | 125 | 101 | 77.5 |
| Basic EPS | 0.97 | 0.99 | 1.01 | 0.83 | 0.67 | 0.51 |
| Diluted EPS | 0.97 | 0.99 | 1.01 | 0.83 | 0.67 | 0.51 |
| Average shares (basic) | 151 | 151 | 151 | 151 | 151 | 151 |
| Average shares (diluted) | 151 | 151 | 151 | 151 | 151 | 151 |
| Dividend per share | 0.18 | 0.16 | 0.15 | 0.13 | — | — |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 282 | 248 | 240 | 248 | 256 | 252 | 231 | 237 | 254 | 234 | 232 | 229 |
| Cost of revenue | 195 | 173 | 160 | 172 | 160 | 168 | 154 | 164 | 167 | 155 | 149 | 154 |
| Gross profit | 86.4 | 75.1 | 79.8 | 76.1 | 95.9 | 83.4 | 77.5 | 72.7 | 87.1 | 79.1 | 83.7 | 74.3 |
| Selling, general and administrative | 35.3 | 32.5 | 33.7 | 32.9 | 32.2 | 33.0 | 32.5 | 30.8 | 31.6 | 31.3 | 31.5 | 31.5 |
| Research and development | 6.3 | 6.0 | 7.3 | 6.4 | 7.3 | 7.2 | 7.1 | 5.4 | 5.7 | 6.9 | 6.3 | 8.0 |
| Operating income | 48.9 | 39.5 | 39.0 | 40.1 | 60.0 | 49.3 | 36.7 | 53.3 | 54.4 | 25.6 | 47.7 | 39.7 |
| EBIT | 48.9 | 39.5 | 39.0 | 40.1 | 60.0 | 49.3 | 36.7 | 53.3 | 54.4 | 25.6 | 47.7 | 39.7 |
| EBITDA | 71.1 | 61.4 | 60.5 | 56.7 | 79.7 | 68.4 | 55.2 | 66.4 | 70.9 | 41.4 | 62.3 | 48.0 |
| Interest expense | 3.9 | 4.0 | 4.0 | 4.7 | 4.9 | 4.8 | 4.8 | 3.7 | 3.7 | 2.9 | 2.6 | 1.8 |
| Pre-tax income | 51.2 | 40.3 | 42.0 | 41.8 | 60.0 | 49.6 | 36.8 | 46.0 | 55.9 | 26.4 | 55.6 | 36.3 |
| Income tax | 12.2 | 9.2 | 8.8 | 8.1 | 14.4 | 11.3 | 7.0 | 11.8 | 9.5 | 1.2 | 11.1 | 1.5 |
| Net income | 38.8 | 31.0 | 33.2 | 33.6 | 45.4 | 38.1 | 29.7 | 34.0 | 46.3 | 25.0 | 44.4 | 34.7 |
| Net income to common shareholders | 38.8 | 31.0 | 33.2 | 33.6 | 45.4 | 38.1 | 29.7 | 34.0 | 46.3 | 25.0 | 44.4 | 34.7 |
| Basic EPS | 0.26 | 0.21 | 0.22 | 0.22 | 0.30 | 0.25 | 0.20 | 0.22 | 0.31 | 0.17 | 0.29 | 0.23 |
| Diluted EPS | 0.26 | 0.21 | 0.22 | 0.22 | 0.30 | 0.25 | 0.20 | 0.22 | 0.31 | 0.17 | 0.29 | 0.23 |
| Average shares (basic) | 149 | 148 | 151 | 151 | 151 | 153 | 148 | 152 | 149 | 147 | 153 | 152 |
| Average shares (diluted) | 149 | 148 | 151 | 151 | 151 | 153 | 148 | 152 | 149 | 147 | 153 | 152 |
| Dividend per share | — | — | — | 0.18 | — | — | — | 0.16 | — | — | — | 0.15 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | FY to Sep 2025 | FY to Sep 2024 | FY to Sep 2023 | FY to Sep 2022 | FY to Sep 2021 | FY to Sep 2020 |
|---|---|---|---|---|---|---|
| Total assets | 1,599 | 1,438 | 1,232 | 1,197 | 740 | 596 |
| Current assets | 681 | 584 | 468 | 555 | 302 | 239 |
| Cash and equivalents | 22.5 | 23.2 | 24.4 | 28.8 | 27.9 | 18.6 |
| Short-term investments | 3.2 | 3.2 | 1.5 | 1.5 | — | — |
| Receivables | 469 | 401 | 290 | 390 | 187 | 154 |
| Inventory | 175 | 146 | 139 | 129 | 83.5 | 63.2 |
| Net property, plant and equipment | 786 | 723 | 638 | 517 | 334 | 267 |
| Goodwill | 28.4 | 29.3 | 29.5 | 31.0 | 29.3 | 28.4 |
| Other intangible assets | 1.3 | 1.1 | 1.5 | 1.9 | 1.7 | 2.6 |
| Long-term investments | 88.5 | 85.1 | 79.1 | 79.8 | 62.3 | 49.5 |
| Current liabilities | 454 | 435 | 351 | 323 | 244 | 210 |
| Accounts payable | 104 | 95.5 | 90.6 | 99.6 | 63.4 | 61.6 |
| Long-term debt | — | — | — | 0.0 | — | — |
| Total debt | 83.0 | 85.8 | 72.3 | 74.8 | 3.6 | 4.2 |
| Total liabilities | 705 | 649 | 540 | 487 | 320 | 280 |
| Total equity (incl. minority) | 894 | 788 | 692 | 709 | 419 | 316 |
| Retained earnings | — | — | 37.0 | 682 | — | — |
| Minority interest | 2.0 | 1.9 | 1.7 | 1.8 | 1.5 | 1.1 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1,694 | 1,610 | 1,628 | 1,599 | 1,528 | 1,486 | 1,480 | 1,438 | 1,399 | 1,359 | 1,241 | 1,232 |
| Current assets | 722 | 669 | 699 | 681 | 648 | 612 | 614 | 584 | 586 | 572 | 465 | 468 |
| Cash and equivalents | 24.9 | 27.8 | 24.6 | 22.5 | 28.3 | 26.1 | 16.8 | 23.2 | 22.2 | 19.0 | 21.3 | 24.4 |
| Short-term investments | 15.0 | 4.5 | 7.5 | 3.2 | 12.9 | — | — | 3.2 | — | — | — | 1.5 |
| Receivables | 486 | 428 | 462 | 469 | 418 | 400 | 410 | 401 | 380 | 374 | 260 | 290 |
| Inventory | 172 | 181 | 183 | 175 | 167 | 155 | 152 | 146 | 145 | 144 | 142 | 139 |
| Net property, plant and equipment | 833 | 804 | 792 | 786 | 748 | 733 | 725 | 723 | 680 | 659 | 654 | 638 |
| Goodwill | — | — | — | 28.4 | — | — | — | 29.3 | — | — | — | 29.5 |
| Other intangible assets | 30.9 | 30.4 | 29.8 | 1.3 | 29.7 | 30.4 | 31.0 | 1.1 | 30.6 | 30.5 | 29.9 | 1.5 |
| Long-term investments | 96.0 | 90.8 | 92.4 | 88.5 | 87.3 | 93.0 | 92.1 | 85.1 | 84.9 | 80.9 | 78.8 | 79.1 |
| Current liabilities | 449 | 422 | 443 | 454 | 413 | 428 | 437 | 435 | 416 | 426 | 298 | 351 |
| Accounts payable | 77.7 | 70.8 | 63.8 | 104 | 76.8 | 79.6 | 79.2 | 95.5 | 91.0 | 74.3 | 77.4 | 90.6 |
| Total debt | 76.9 | 77.7 | 78.4 | 83.0 | 80.4 | 80.8 | 80.4 | 85.8 | 81.1 | 67.8 | — | — |
| Total liabilities | 696 | 666 | 695 | 705 | 663 | 647 | 648 | 649 | 630 | 631 | 520 | 540 |
| Total equity (incl. minority) | 998 | 944 | 932 | 894 | 865 | 839 | 832 | 788 | 769 | 728 | 721 | 692 |
| Retained earnings | 359 | 320 | 316 | — | — | — | — | — | — | — | — | — |
| Minority interest | 2.2 | 1.9 | 2.1 | 2.0 | 1.8 | 2.2 | 2.0 | 1.9 | 1.7 | 2.1 | 1.9 | 1.7 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | FY to Sep 2025 | FY to Sep 2024 | FY to Sep 2023 | FY to Sep 2022 | FY to Sep 2021 | FY to Sep 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | 180 | 225 | 182 | 182 | 132 | 104 |
| Depreciation and amortization | 79.4 | 65.0 | 51.8 | 43.8 | 36.4 | 33.7 |
| Capital expenditure | -144 | -145 | -175 | -152 | -98.1 | -85.2 |
| Investing cash flow | -159 | -255 | -171 | -142 | -95.9 | -81.2 |
| Financing cash flow | -21.1 | 31.9 | -11.4 | -42.4 | -27.5 | -14.4 |
| Dividends paid | -24.1 | -22.6 | -18.9 | -11.5 | -39.8 | -44.0 |
| Debt issued | 16.7 | 61.9 | 0.0 | 1.0 | — | 0.7 |
| Debt repaid | -4.8 | -3.6 | -4.3 | -1.5 | -1.6 | -0.9 |
| Effect of exchange rates | -0.5 | -2.4 | -3.3 | 3.3 | 0.4 | -5.8 |
| Net change in cash | -0.7 | -1.2 | -4.4 | 0.9 | 9.3 | 2.9 |
| Free cash flow | 35.6 | 79.7 | 6.2 | 30.1 | 34.1 | — |
| Levered free cash flow | -59.0 | -66.1 | 72.6 | -202 | -21.3 | — |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 45.6 | 91.7 | 3.4 | 52.3 | 55.2 | 47.5 | 25.1 | 75.4 | 57.9 | 25.4 | 66.0 | 41.6 |
| Depreciation and amortization | 22.2 | 21.9 | 21.4 | 22.1 | 19.7 | 19.1 | 18.5 | 18.0 | 16.5 | 15.8 | 14.6 | 13.9 |
| Capital expenditure | -32.3 | -26.6 | -23.4 | -55.4 | -38.0 | -29.8 | -21.1 | -64.6 | -23.9 | -28.2 | -28.5 | -88.8 |
| Investing cash flow | -48.2 | -13.9 | -43.7 | -70.9 | -43.2 | 8.8 | -59.6 | -174 | -24.2 | -28.6 | -28.6 | -85.1 |
| Financing cash flow | -0.7 | -75.5 | 42.6 | 12.6 | -9.1 | -47.6 | 28.6 | 101 | -30.0 | 0.8 | -39.6 | 47.5 |
| Dividends paid | 0.0 | -27.1 | — | 0.0 | 0.0 | -24.1 | — | 0.0 | 0.0 | -22.6 | — | — |
| Debt issued | — | — | — | 16.6 | — | — | — | 61.9 | -1.0 | 0.7 | 0.3 | -0.3 |
| Debt repaid | -1.0 | -1.0 | -0.9 | -0.9 | -0.9 | -0.9 | -2.1 | -1.2 | -1.0 | -0.7 | -0.7 | -1.5 |
| Effect of exchange rates | 0.4 | 0.8 | -0.2 | 0.1 | -0.7 | 0.6 | -0.5 | -1.0 | -0.5 | -0.0 | -0.9 | -0.5 |
| Net change in cash | -2.9 | 3.2 | 2.1 | -5.8 | 2.2 | 9.3 | -6.4 | 1.0 | 3.1 | -2.3 | -3.0 | 3.5 |
| Free cash flow | 13.3 | 65.1 | -20.0 | -3.1 | 17.2 | 17.7 | 4.0 | 10.9 | 34.0 | -2.8 | 37.5 | -47.2 |
| Levered free cash flow | -17.0 | 73.8 | -54.7 | -21.6 | -28.9 | 36.8 | -45.1 | -6.8 | 40.8 | -93.0 | -12.0 | -36.4 |
Financial statements of similar companies
Companies in the group: same industry, similar size